Vaccine Development Professionals to Know 2025

Emanuele Andreano is an immunologist and biotech innovator redefining how vaccines are discovered for pandemic threats. As Head of Serology and Immunology at the Fondazione Biotecnopolo di Siena and a leader in the European Vaccine Hub, he works at the intersection of AI, immunology, and global health. He pioneered Reverse Vaccinology 3.0, a breakthrough approach that can identify entirely new vaccine targets in days instead of years. In a first-of-its-kind demonstration, his team showed that artificial intelligence can predict unknown viral antigens directly from human antibody sequences—effectively reversing the traditional vaccine discovery process. His work spans monoclonal antibody discovery and next-generation vaccines against emerging pathogens, including mpox and SARS-CoV-2, with direct implications for global pandemic preparedness and biosecurity. Andreano has received international recognition, including the Antonio Feltrinelli Prize from the Accademia Nazionale dei Lincei, awarded in the presence of the President of the Italian Republic Sergio Mattarella, the IUIS Rising Star in Immunology, and a European Research Council (ERC) grant. He also co-directs a vaccinology program at the Institut Pasteur in Paris. “We are entering an era where vaccines can be discovered at unprecedented speed—transforming our ability to fight pandemics and save countless lives.”

Bacterial Immunologist with 12+ years research experience advancing vaccine development, systems immunology, and functional antibody therapeutics at premier institutions and industry leaders.

Dr. James Utley is a pioneering scientist at the forefront of cellular therapy, AI, and data science. A Johns Hopkins-educated Immunohematology expert and Certified Advanced Biotherapies Professional (CABP), he also holds advanced certifications in data science and machine learning. While serving as Technical Director at a major healthcare organization, Dr. Utley oversaw more than 150,000 successful cellular transfusions and spearheaded advancements that significantly improved patient outcomes. This experience included leading initiatives for the Department of Defense, where he revolutionized cellular transfusion practices. His innovative approach is further exemplified by his FDA-approved work and numerous publications in leading scientific journals. Dr. Utley is also known for his bold, hands-on approach to research, embodying the spirit of a "biohacker" by pushing the boundaries of CRISPR and genetic engineering through self-experimentation. This unique blend of rigorous scientific training and unconventional methods has earned him the moniker "the pirate" within the biohacker community.

Experienced immunologist and biotechnology researcher with 5+ years of expertise in cellular and molecular immunology, translational research, and immunoassay development. Proven track record across leading academic and industry institutions, including Harvard Medical School, Moderna, Eurofins, and AIIMS Nagpur. Skilled in flow cytometry, ELISA optimization, cell culture, molecular biology, and immune cell characterization, with hands-on experience in vaccine research, cytokine biology, and tumor immunology. Recognized for scientific innovation, collaborative leadership, and mentoring excellence, with multiple awards, peer-reviewed publications, and international research presentations. Passionate about advancing immunological research from bench to translational applications through rigorous experimentation and interdisciplinary collaboration.

Gravity Base is an AI solutions and automation company in Dubai, UAE, helping businesses accelerate growth through intelligent, scalable, and secure artificial intelligence solutions. We specialize in custom AI development, AI agents, generative AI, large language model (LLM) integrations, AI chatbots, workflow automation, retrieval-augmented generation (RAG), and enterprise AI solutions tailored to business needs. Our team designs and develops AI-powered applications that automate repetitive tasks, improve customer experiences, enhance decision-making, and increase operational efficiency. Whether you need an AI chatbot for customer support, AI agents for business processes, document intelligence, knowledge management, or custom AI software, Gravity Base delivers solutions built for performance, security, and scalability. Our services include AI consulting, AI strategy, generative AI development, AI agent development, chatbot development, workflow automation, LLM integration, RAG implementation, machine learning solutions, AI software development, API integration, and enterprise AI transformation. We work with startups, SMEs, and enterprise organizations across industries to implement practical AI solutions that deliver measurable business value. At Gravity Base, we combine technical expertise with business strategy to create AI systems that integrate seamlessly with existing workflows and support long-term digital transformation. By following industry best practices, responsible AI principles, and modern AI search optimization techniques, we help organizations stay competitive in an AI-driven world. If you're looking for a trusted AI development company in Dubai, an experienced AI automation partner in the UAE, or experts in Generative AI, AI agents, and enterprise AI solutions, Gravity Base provides innovative, reliable, and future-ready AI services that drive business growth.

Dr. Shahadat Hussain is a Materials Scientist and Mechanical Engineer based in Abu Dhabi, UAE. He currently serves as an Associate Research Scientist in the Division of Engineering at New York University Abu Dhabi (NYUAD). His research focuses on the design, fabrication, and mechanical characterization of advanced architected materials and shape memory alloys. Dr. Hussain specializes in Triply Periodic Minimal Surface (TPMS) metamaterials and NiTi (Nitinol) shape memory alloys. His work investigates the process-structure-property relationships in materials fabricated via Laser Powder Bed Fusion (LPBF) and polymer-based additive manufacturing. A significant portion of his research examines how specific print parameters—such as laser power, scan speed, and energy density—dictate the microstructural evolution, phase transformation behavior, and mechanical performance of complex lattice geometries, including Gyroid and Schwarz Primitive topologies. With over a decade of experience in materials engineering, Dr. Hussain possesses comprehensive, hands-on expertise across the entire experimental pipeline. He is proficient in operating metal and polymer additive manufacturing systems, alongside rigorous materials characterization techniques including Scanning Electron Microscopy (SEM), X-ray Diffraction (XRD), and Differential Scanning Calorimetry (DSC). He also conducts extensive mechanical testing, including tensile, compression, and fatigue analysis, in accordance with ASTM and ISO standards. He holds a PhD in Materials Science and Technology from the Academy of Scientific and Innovative Research (AcSIR) at CSIR-AMPRI, India, and a Bachelor of Engineering in Mechanical Engineering. Prior to his current role, he completed a postdoctoral fellowship at Khalifa University, focusing on defect reduction and phase control in additively manufactured smart alloys. He has authored numerous peer-reviewed publications, accumulating over 500 citations and an h-index of 10. Dr. Hussain is available to provide expert commentary to media and industry professionals on topics related to additive manufacturing, metamaterials, shape memory alloys, mechanical testing, and materials science research and development in the United Arab Emirates.

Macay Hunter is a manufacturing executive specializing in custom plastic component production, with expertise spanning injection molding, structural foam molding, and advanced polymer processing technologies. He currently serves in a senior commercial leadership role, where he focuses on helping OEMs and product manufacturers bring complex plastic parts from concept through production. Macay’s work sits at the intersection of engineering, operations, and supply chain strategy. He partners closely with mechanical engineers, sourcing leaders, and program managers to evaluate manufacturability, tooling strategy, material selection, and long-term production scalability. His experience supports programs across highly regulated and performance-critical sectors, including medical device, aerospace and defense, industrial equipment, and commercial products. Known for a consultative and design-for-manufacturability driven approach, Macay is particularly focused on aligning part design, process selection, and tooling investment with program risk, lifecycle demand, and cost optimization. He frequently collaborates with customers early in development to identify geometry improvements, cycle time efficiencies, and structural performance enhancements before production launch. In addition to commercial leadership, Macay is actively engaged in building modern sales and marketing infrastructure within the manufacturing sector. He leverages digital prospecting tools, intent data, and CRM automation to develop scalable top-of-funnel engagement strategies that connect engineering organizations with the right manufacturing partners. Macay is an advocate for U.S. manufacturing and supplier partnership models that balance quality control, capacity resilience, and supply chain continuity. Through industry engagement and thought leadership, he contributes perspectives on sourcing strategy, tooling investment, and production risk management in complex plastic part programs.

Vincent Caradec is the French CEO and Co-Founder of Healthi Life (healthi-life.com), Bangkok's Urban Longevity House — a physician-led longevity, preventive and regenerative medicine clinic serving 50+ nationalities. Available for expert commentary on: - Building a longevity clinic in Asia - Medical tourism market trends in Thailand and Southeast Asia - CEO insights on preventive medicine adoption - GLP-1 weight management market (Tirzepatide, Retatrutide, Mounjaro, Wegovy) - Stem cell, exosome and NAD+ regenerative therapies - 300+ biomarker testing programs and longevity diagnostics - Wellness industry business strategy and pricing - Asian healthcare entrepreneurship Healthi Life operates an integrated longevity center offering check-ups, 3-12 month longevity programs, corporate wellness contracts and advanced regenerative therapies (stem cells, exosomes, NAD+, peptides, IV therapy). French national based in Bangkok. Fluent in English and French. Available for interviews on Zoom, Google Meet, WhatsApp.

Founder of Peptides.io, an independent educational platform dedicated to making peptide research easier to understand. I focus on translating peer-reviewed science into practical, evidence-based content covering longevity, metabolic health, recovery, weight management, and emerging peptide therapies. My work emphasizes transparency, critical evaluation of research, and helping readers separate evidence from marketing claims. Peptides.io does not provide medical advice or sell peptides—we aim to make complex research more accessible and understandable.

Vardan Ter-Antonyan is a scientist, operator, author, entrepreneur, and executive who has spent more than two decades inside pharmaceutical and regulated environments, advancing from technical roles into senior leadership and C-suite responsibility. His experience spans organizations ranging from early-stage ventures to large-scale enterprises with thousands of employees. Having worked at the intersection of science, operations, and executive governance, Vardan has observed firsthand how leadership decisions are actually made, particularly the often-unspoken criteria organizations use when selecting executives. C-Suite Bible reflects those observations, informed by both his own tenure in senior roles and his exposure to CXO transitions. In addition to his corporate leadership experience, Vardan has founded and advised businesses, further deepening his perspective on risk, capital allocation, and institutional trust. He holds a Master’s degree in Molecular Biophysics, is a Lean Six Sigma Master Black Belt, and is pursuing a Doctor of Business Administration degree. Throughout his career, Vardan has led multidisciplinary R&D teams, developed novel drug delivery systems, optimized manufacturing processes, and helped organizations bring innovative products to market while navigating complex regulatory requirements. His technical expertise includes lipid-based drug delivery systems, nanoemulsions, self-emulsifying drug delivery systems (SEDDS/SNEDDS), liposomes, controlled-release technologies, and formulation development for poorly water-soluble compounds. In addition to his scientific leadership, Vardan is passionate about bridging the gap between research and commercial success. He regularly advises companies on product development strategy, technology commercialization, operational excellence, and innovation management. His work combines deep scientific knowledge with practical business insight, enabling organizations to accelerate development timelines, improve product quality, and reduce technical risk. Vardan is also an author, speaker, and industry thought leader who enjoys sharing evidence-based perspectives on pharmaceutical innovation, drug delivery, biotechnology, diagnostics, manufacturing, and executive leadership. He welcomes opportunities to provide expert commentary for journalists covering advances in pharmaceutical science, healthcare innovation, biotechnology, regulatory affairs, and emerging medical technologies.

Dan Pierce, MD, is a rehabilitation medicine physician and healthcare quality expert who helps reporters cover what happens after the initial injury - recovery, disability, and the long-term cost of care. An Assistant Professor at the University of Nebraska Medical Center, he holds physician leadership roles across academic, community, and VA health systems, serves in the AMA House of Delegates, and advises Nebraska's Medicaid program. He can speak to brain injury, spinal cord injury, and stroke recovery, Veterans' health, quality and safety, Medicare/Medicaid policy, and health system sustainability.

Clinical trial management of two stem cell clinical trials. I have a passion for data science analytics and rigorous pattern-seeking. I believe in leading from the front and making sure the team is well taken care of. *Managing 2 stem cell clinical trials, NCT02838316 and NCT05421689*30 peer-reviewed publications.*>12,000 citations.*2 provisional patents.*Co-founded startup.*Co-developed departmental leadership program.*Strong track record of grant funding and collaboration building.* Associated Editor for two flagship scientific journals (Stem Cells, Journal of Extracellular Biology).GOOGLE SCHOLAR PROFILEhttps://scholar.google.com/citations?user=3uQtjEEAAAAJ&hl=en

I entered the hemp space at the very beginning when there were almost no guardrails, no industry playbook, and very few operators who truly understood what it took to formulate something that actually worked. Hemp-derived flower and hemp wellness products were barely a category. What existed was largely untested, poorly sourced, and built around novelty rather than need. From day one, our approach was different purpose before profit, formulation before marketing, and a deep belief that every formulation should serve a real purpose. At JustKana, I oversee product development, quality control, and sourcing from the ground up. That means building relationships directly with small-batch organic hemp farms, evaluating raw material quality before it ever reaches a formulation stage, and ensuring every finished product meets both our internal standards and third-party lab verification. My work lives at the intersection of plant science and consumer wellness. I specialize in cannabinoid formulation for real therapeutic outcomes sleep support, chronic pain relief, anxiety management, and inflammation using full-spectrum hemp extracts that preserve the natural compound profile of the plant rather than isolating single ingredients. Over the years I've helped develop products that have made a measurable difference for thousands of people veterans managing PTSD, seniors dealing with chronic joint pain, and individuals looking to replace pharmaceutical sleep aids with something cleaner and plant-derived. That direct connection to consumer outcomes shapes every formulation decision I make. I understand the hemp supply chain from soil to finished product cultivation practices, extraction methods, cannabinoid and terpene profiles, and how sourcing decisions downstream directly impact what a customer experiences. In a space flooded with white-labeled, mass-produced products, that depth of knowledge is rare.

Dr. Frank D. Yelian, MD, PhD, is the Founder and Director of Life IVF Center, one of the West Coast's largest independent fertility practices. At Life IVF, he leads a highly specialized fertility program focused on delivering results in the most challenging cases. With dual training as a physician and scientist, Dr. Yelian combines rigorous clinical expertise with a deep understanding of reproductive biology to develop highly individualized treatment strategies. Dr. Yelian is widely recognized for his work with patients who have experienced prior IVF failure, particularly those with diminished ovarian reserve (DOR), advanced maternal age, and other complex diagnoses. His clinical approach centers on Precision IVF® protocols, which emphasize careful calibration of medication dosing to align with each patient’s unique physiology. This method is designed to maximize treatment effectiveness while reducing unnecessary medication costs and limiting exposure to potentially harmful side effects. At Life IVF Center, Dr. Yelian has built a reputation for treating patients that many clinics decline. His program consistently achieves successful outcomes in cases considered low probability, supported by advanced diagnostics, refined stimulation strategies, and a high-performance embryology laboratory. In addition to his work with complex IVF cases, Dr. Yelian has extensive experience in travel IVF, egg donation, and gestational surrogacy, providing comprehensive solutions for both domestic and international patients. His ability to manage intricate clinical scenarios across these pathways has made Life IVF Center a destination for patients seeking expertise beyond standard fertility care. Dr. Yelian’s work is defined by a commitment to precision, innovation, and results, establishing Life IVF Center as a leader in advanced reproductive medicine for patients who require a more sophisticated and individualized approach.

Adrian Wadowski is the Brand Director at CamelWay, Europe's premier producer of functional camel milk. He is a leading voice on the therapeutic applications of alternative dairy, specifically for metabolic health (Type 1 & 2 Diabetes) and autoimmune support. Adrian specializes in the "Gut-Skin Axis", educating on how Lactoferrin and IgG can support recovery from Eczema and Psoriasis. He is also an advocate for Casomorphin-free (GFCF) diets to support neurodiversity and Autism therapy. He oversees EU-certified production using advanced low-temperature spray drying technology, ensuring the preservation of bioactive proteins often lost in standard processing.

Dr. Akshaya Srikanth Bhagavathula is an Associate Professor of Epidemiology at North Dakota State University, internationally recognized for his pioneering work at the intersection of digital epidemiology, pharmacovigilance, and artificial intelligence. His research harnesses advanced statistical modeling and AI to track and predict health behaviors, medication safety, and disease patterns in real time—bridging traditional epidemiology with next-generation digital health analytics. Dr. Bhagavathula has published more than 250 peer-reviewed articles in leading journals, including Annals of Epidemiology, JAMA Network Open, and Lancet Digital Health. His work has been widely cited and featured in major media outlets such as The New York Times, where he discussed the real-world safety of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy, Mounjaro). Recognized among the Stanford–Elsevier Top 2% of Scientists (2019–2024) and elected as a Fellow of the American College of Epidemiology, Dr. Bhagavathula is known for translating complex data into actionable insights that shape public health policy and clinical practice. His ongoing projects include NIH- and NSF-aligned initiatives on AI-powered overdose forecasting, digital twins for public health, and real-world drug safety surveillance using explainable machine learning. With a decade of experience spanning more than two dozen countries and collaborations with organizations such as WHO, USAID, and UNICEF, Dr. Bhagavathula brings a global, data-driven, and human-centered approach to solving modern health crises.

I am an MD-PhD physician-scientist with a passion for translating complex clinical and scientific data into clear, accurate content. My training and experience span clinical practice and translational research, with expertise across oncology, immunology, gastroenterology, inflammation & metabolism, and rare diseases. With over 10 years of experience, I have supported key deliverables including more than 30 peer-reviewed publications, manuscripts, slide decks, literature reviews, and scientific narratives. I enjoy working in collaborative, deadline-driven environments and am particularly interested in medical writing, medical information, and publication development, where scientific accuracy and effective storytelling intersect.

Shane Hellmrich holds a BSc in Health Promotion and has spent the past 11 years independently testing and reviewing online modafinil vendors — placing personal test orders, verifying product authenticity, and documenting shipping reliability across dozens of suppliers. His work at BuyModa.net tracks over 1,300 verified customer transactions and maintains a public testing methodology that has become a trusted reference point for consumers navigating the grey-market pharmaceutical space. Shane's research covers vendor reliability scoring, product authentication, shipping logistics across international jurisdictions, and the pharmacokinetic profiles of generic modafinil products. He is regularly consulted on topics including nootropics and cognitive enhancement, online pharmacy safety and regulation, pharmaceutical sourcing and supply chain transparency, consumer protection in unregulated markets, and the real-world usage patterns of prescription cognitive enhancers. Shane is available for expert commentary, background briefings, and on-the-record quotes for journalists covering health, productivity, pharmacology, biohacking, and consumer safety.

Clinically trained veterinarian with experience in gastroenterology, internal medicine, and emergency care. Veterinary physician-scientist specializing in clinical research, diagnostic development, and translational medicine in companion animals, supporting research initiatives in oncology and internal medicine. Skilled in clinical sample characterization and biobank operations, including medical record review of 4,000+ veterinary cases and collaboration with academic and clinical partners. Holds a PhD in Biomedical Sciences focused on cell biology and organoid technology with multiple pending patents, with experience in disease modeling and scientific publication. Regularly collaborates with senior leadership to align cross-functional teams and advance complex research initiatives, complemented by an MBA focused on strategy and project management.

Dr. Boluwatife OLU Afolabi is a dental surgeon and PhD candidate in Oral Biology at the University of Minnesota School of Dentistry. His research examines the molecular and epigenetic mechanisms that drive head and neck squamous cell carcinoma, with particular emphasis on environmental carcinogens, inflammatory signaling, and transcriptional regulation during malignant transformation. His current work investigates the Aryl Hydrocarbon Receptor (AHR) and S100A8/S100A9-mediated epithelial inflammatory responses using cellular and molecular models of oral cancer. His broader expertise spans cancer biology, oral pathology, environmental toxicology, molecular biology, and translational biomedical research. Dr. Afolabi can provide expert perspective on oral and head-and-neck cancer, cancer risk factors, environmental carcinogen exposure, inflammation and disease mechanisms, oral-systemic health, cancer prevention, and emerging developments in cancer biology. He is particularly interested in translating mechanistic research into a clearer understanding of cancer susceptibility, prevention, biomarkers, and therapeutic opportunities.